Abstract
This paper has two purposes. The first is to examine whether increased medication of inhaled corticosteroids by asthmatic patients is correlated with an improvement in asthma control, measured as a reduction in asthma hospitalizations. The other purpose, if such a relationship can be established, is to analyse the economic consequences. Regional data on asthma hospitalization, i.e. number of bed-days, and sales of anti-asthmatic drugs from 14 regions in Sweden between 1978 and 1989 were used (covering 71% of the Swedish population). The data were analysed in multivariate pooled cross-section, time-series regressions. The variation in bed-days was explained by three variables: the sales of inhaled corticosteroids; total supply of in-patient care; and sales of inhaled bronchodilators, which were used as a proxy for asthma prevalence. The results indicate that sales of inhaled corticosteroids are significantly correlated with decreased hospitalizations for asthma. Assuming that the correlation also reflects a causal relationship, an increase in sales of inhaled corticosteroids by 1 defined daily dose (DDD) per day and 1000 inhabitants gave, on average over the study period, a reduction of 1.7 bed-days for asthma in in-patient care per 1000 inhabitants.
Original language | English |
---|---|
Pages (from-to) | 1591-1599 |
Number of pages | 9 |
Journal | Applied Economics |
Volume | 28 |
Issue number | 12 |
DOIs | |
Publication status | Published - 1996 Jan 1 |
Externally published | Yes |
Subject classification (UKÄ)
- Economics